 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

This price move could be a signal that ALT may fall back below the higher band and head toward the middle band. Traders may consider selling the stock, shorting the stock, or exploring put options...

Altimmune (ALT, $3.56) price may drop as it broke higher Bollinger Band on Dec 01, 2023

Altimmune Inc (NASDAQ: ALT) announced topline results from its 48-week MOMENTUM Phase 2 obesity trial of pemvidutide read more...

Tale Of Two Investigational Obesity Drugs: Altimmune Stock Jumps, While Pfizer Trades Lower

Achieved mean weight loss of 15.6% on 2.4 mg dose of pemvidutide at Week 48, with weight loss continuing at the end of treatmentOver 30% of subjects achieved 20% or more weight loss on 2.4 mg dose at...

Altimmune Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide

This is a signal that ALT's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Altimmune (ALT, $3.06) RSI Indicator left the overbought zone on November 27, 2023

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Altimmune (ALT Research Report) and SurModics (SRD...

Analysts Offer Insights on Healthcare Companies: Altimmune (ALT) and SurModics (SRDX)

Top-line 48-week results from the MOMENTUM Phase 2 obesity trial expected Q4 2023 Pemvidutide granted Fast Track designation for the treatment of non-alcoholic steatohepatitis (NASH) Top-line...

Altimmune Announces Third Quarter 2023 Financial Results and Provides a Business Update

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Seagen (SGEN Research Report) and Altimmune (ALT...

Analysts Offer Insights on Healthcare Companies: Seagen (SGEN) and Altimmune (ALT)

GAITHERSBURG, Md., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter 2023 financial...

Altimmune to Report Third Quarter 2023 Financial Results and Provide Business Update on November 7, 2023

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Altimmune granted Fast Track designation by FDA for pemvidutide

GAITHERSBURG, Md., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has...

Altimmune Granted Fast Track Designation by FDA for Pemvidutide for the Treatment of Non-Alcoholic Steatohepatitis (NASH)

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Watchers	25,787
52-Wk Low	$2.09
52-Wk High	$17.17

Market Cap	$191.81M
Volume (M)	179,966.00
52-Wk High	$17.17
52-Wk Low	$2.09

Current Price	$4.63
Prev Close	$3.57
Open	$4.10
Dividend Yield	0.00%
50-Day Moving Average	$2.63
Beta	1.16
Avg. Volume	1.5M
PE Ratio	-3.01

52-Week High	$17.17
52-Week Low	$2.09
Market Capitalization	$191.81M
EPS	-$1.54
Price to Book	1.63
Revenue Per Employee	$5,365.39
Enterprise Value/EBITDA	0.01

ALT Altimmune Inc

About

Feed

News

Sentiment

Earnings

Fundamentals